Lessons learned : establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays - navigating the transition from research to clinical practice
© 2024. The Author(s)..
Mass spectrometry (MS) assays offer exceptional capabilities in high multiplexity, specificity, and throughput. As proteomics technologies continue advancements to identify new disease biomarkers, transition of these innovations from research settings to clinical applications becomes imperative. To meet the rigorous regulatory standards of clinical laboratories, development of a clinical protein MS assay necessitates adherence to stringent criteria. To illustrate the process, this project focused on using thyroglobulin (Tg) as a biomarker and an immuno-multiple reaction monitoring (iMRM) MS-based assay as a model for establishing a Clinical Laboratory Improvement Amendments (CLIA) compliant laboratory within the Centers of Genomic and Precision Medicine, National Taiwan University. The chosen example also illustrates the clinical utility of MS assays to complement conventional immunoassay-based methods, particularly in cases where the presence of autoantibodies in 10-30% of patients hinders accuracy. The laboratory design entails a comprehensive coordination in spatial layout, workflow organization, equipment selection, ventilation systems, plumbing, electrical infrastructure, documentation procedures, and communication protocols. Practical aspects of the transformation process, including preparing laboratory facilities, testing environments, instrument validation, assay development and validation, quality management, sample testing, and personnel competency, are discussed. Finally, concordant results in proficiency testing demonstrate the harmonization with the University of Washington Medical Center and the quality assurance of the CLIA-equivalent Tg-iMRM MS assay established in Taiwan. The realization of this model protein MS assay in Taiwan highlights the feasibility of international joint development and provides a detailed reference map to expedite the implementation of more MS-based protein assays in clinical laboratories for patient care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical proteomics - 21(2024), 1 vom: 22. Feb., Seite 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Chia-Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical laboratory improvement amendments (CLIA) |
|---|
| Anmerkungen: |
Date Revised 25.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s12014-024-09455-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36879041X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36879041X | ||
| 003 | DE-627 | ||
| 005 | 20240229151744.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12014-024-09455-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1305.xml |
| 035 | |a (DE-627)NLM36879041X | ||
| 035 | |a (NLM)38389054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Chia-Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lessons learned |b establishing a CLIA-equivalent laboratory for targeted mass spectrometry assays - navigating the transition from research to clinical practice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Mass spectrometry (MS) assays offer exceptional capabilities in high multiplexity, specificity, and throughput. As proteomics technologies continue advancements to identify new disease biomarkers, transition of these innovations from research settings to clinical applications becomes imperative. To meet the rigorous regulatory standards of clinical laboratories, development of a clinical protein MS assay necessitates adherence to stringent criteria. To illustrate the process, this project focused on using thyroglobulin (Tg) as a biomarker and an immuno-multiple reaction monitoring (iMRM) MS-based assay as a model for establishing a Clinical Laboratory Improvement Amendments (CLIA) compliant laboratory within the Centers of Genomic and Precision Medicine, National Taiwan University. The chosen example also illustrates the clinical utility of MS assays to complement conventional immunoassay-based methods, particularly in cases where the presence of autoantibodies in 10-30% of patients hinders accuracy. The laboratory design entails a comprehensive coordination in spatial layout, workflow organization, equipment selection, ventilation systems, plumbing, electrical infrastructure, documentation procedures, and communication protocols. Practical aspects of the transformation process, including preparing laboratory facilities, testing environments, instrument validation, assay development and validation, quality management, sample testing, and personnel competency, are discussed. Finally, concordant results in proficiency testing demonstrate the harmonization with the University of Washington Medical Center and the quality assurance of the CLIA-equivalent Tg-iMRM MS assay established in Taiwan. The realization of this model protein MS assay in Taiwan highlights the feasibility of international joint development and provides a detailed reference map to expedite the implementation of more MS-based protein assays in clinical laboratories for patient care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Clinical laboratory improvement amendments (CLIA) | |
| 650 | 4 | |a Immuno-multiple reaction monitoring (iMRM) mass spectrometry | |
| 650 | 4 | |a Targeted mass spectrometry | |
| 650 | 4 | |a Thyroglobulin assay | |
| 700 | 1 | |a Lai, Chi-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Reyes, Aaron James |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hao-Chin |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jin-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Shih, Shyang-Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kuen-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Hoofnagle, Andrew N |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Sung-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Bocik, William |e verfasserin |4 aut | |
| 700 | 1 | |a Hiltke, Tara |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Huan-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Ching-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu-Ju |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical proteomics |d 2006 |g 21(2024), 1 vom: 22. Feb., Seite 12 |w (DE-627)NLM195115023 |x 1542-6416 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:22 |g month:02 |g pages:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12014-024-09455-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 1 |b 22 |c 02 |h 12 | ||